Skip to content

13F-HR filed by Merck & Co., Inc.

Merck & Co., Inc. filed this 13F-HR for the quarter ended 2025-09-30, filed 2025-11-12, with 13 holding rows worth $228,030,003.

Accession
0000310158-25-000063
Filed
2025-11-12
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2025

A holdings report, 13 entries on the cover page, a total value of $228,030,003 stated on the cover page (in dollars after the unit check, H1), rows summing to $228,030,003 with VALUE read as dollars as filed, 13F file number 028-25193. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
PERSONALIS INC71535D106COMMON STOCK14,044,943$91,573,028dollars as filed
MODERNA INC60770K107COM2,308,190$59,620,548dollars as filed
KYMERA THERAPEUTICS INC501575104COM772,165$43,704,539dollars as filed
ALECTOR INC014442107COMMON STOCK3,545,719$10,495,328dollars as filed
ENTRADA THERAPEUTICS INC29384C908COM1,739,768$10,090,654dollars as filed
EVAXION BIOTECH A/S29970R204SPONSORED ADS1,214,126$4,565,114dollars as filed
SUTRO BIOPHARMA INC869367102COM2,723,509$2,365,095dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM93,414$2,015,874dollars as filed
LAVA THERAPEUTICS NVN51517105SHS1,149,345$1,792,978dollars as filed
Xilio Therapeutics Inc.98422T100COM1,483,758$1,250,363dollars as filed
CARISMA THERAPEUTICS INC14216R101COM1,473,240$403,668dollars as filed
NEUPHORIA THERAPEUTICS INC64136E102COM10,027$118,218dollars as filed
TUHURA BIOSCIENCES INC898920103COM13,950$34,596dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000310158-25-000063this filing2025-11-12acceptance time not in the bulk data set